Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15396540 | 0.91 | SMN1; SMN2 (0.70) | SMN1; SMN2ADORA2BMAPTRXFP1NPSR1 | |
| SCHEMBL12686356 | 0.89 | SMN1; SMN2 (0.68) | SMN1; SMN2ADORA2BMAPTRXFP1NPSR1 | |
| SCHEMBL12260494 | 0.85 | SMN1; SMN2 (0.76) | SMN1; SMN2ADORA2BMAPTRXFP1NPSR1 | |
| SCHEMBL10850696 | 0.83 | SMN1; SMN2 (0.82) | SMN1; SMN2ADORA2BMAPTRXFP1NPSR1 | |
| SCHEMBL17635429 | 0.83 | SMN1; SMN2 (0.62) | SMN1; SMN2ADORA2BMAPTRXFP1NPSR1 | |
| SCHEMBL10178027 | 0.82 | SMN1; SMN2 (1.00) | SMN1; SMN2ADORA2BMAPTRXFP1NPSR1 | |
| SCHEMBL10178054 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2ADORA2BMAPTRXFP1NPSR1 | |
| SCHEMBL20715459 | 0.81 | RXFP1 (0.58) | SMN1; SMN2ADORA2BMAPTRXFP1NPSR1 | |
| SCHEMBL10850700 | 0.80 | SMN1; SMN2 (0.76) | SMN1; SMN2ADORA2BMAPTRXFP1NPSR1 | |
| SCHEMBL25295543 | 0.80 | LMNA (0.56) | SMN1; SMN2ADORA2BMAPTRXFP1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066413-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION | METRO INTERNATIONAL BIOTECH, LLC | 2025-02-27 | — | — | US | disclosed |
| EP-4452279-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION | Metro International Biotech, LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023122190-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION | METRO INTERNATIONAL BIOTECH, LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122190-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION | METRO INTERNATIONAL BIOTECH, LLC (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066413-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION | NQO1, NAMPT, MPO | SMN1; SMN2 3260/4885ADORA2B 1104/4885MAPT 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.